ATE518879T1 - Verfahren zur herstellung eines partiellen orf2 proteins des hepatitis e virus - Google Patents

Verfahren zur herstellung eines partiellen orf2 proteins des hepatitis e virus

Info

Publication number
ATE518879T1
ATE518879T1 AT95936312T AT95936312T ATE518879T1 AT E518879 T1 ATE518879 T1 AT E518879T1 AT 95936312 T AT95936312 T AT 95936312T AT 95936312 T AT95936312 T AT 95936312T AT E518879 T1 ATE518879 T1 AT E518879T1
Authority
AT
Austria
Prior art keywords
hepatitis
virus
partial
producing
sar
Prior art date
Application number
AT95936312T
Other languages
English (en)
Inventor
Sergei Tsarev
Suzanne Emerson
Robert Purcell
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/316,765 external-priority patent/US6706873B1/en
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE518879T1 publication Critical patent/ATE518879T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/28011—Hepeviridae
    • C12N2770/28111—Hepevirus, e.g. hepatitis E virus
    • C12N2770/28122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/28011—Hepeviridae
    • C12N2770/28111—Hepevirus, e.g. hepatitis E virus
    • C12N2770/28123—Virus like particles [VLP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT95936312T 1994-10-03 1995-10-03 Verfahren zur herstellung eines partiellen orf2 proteins des hepatitis e virus ATE518879T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/316,765 US6706873B1 (en) 1992-09-18 1994-10-03 Recombinant proteins of a pakistani strain of hepatitis E and their use in diagnostic methods and vaccines
PCT/US1995/013102 WO1996010580A2 (en) 1994-10-03 1995-10-03 Recombinant proteins of a pakistani strain of hepatitis e and their use in diagnostic methods and vaccines

Publications (1)

Publication Number Publication Date
ATE518879T1 true ATE518879T1 (de) 2011-08-15

Family

ID=23230582

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95936312T ATE518879T1 (de) 1994-10-03 1995-10-03 Verfahren zur herstellung eines partiellen orf2 proteins des hepatitis e virus

Country Status (9)

Country Link
EP (1) EP0784631B1 (de)
JP (1) JP3889808B2 (de)
KR (1) KR100359526B1 (de)
CN (1) CN1148450C (de)
AT (1) ATE518879T1 (de)
AU (1) AU712901B2 (de)
NO (1) NO326399B1 (de)
NZ (1) NZ295056A (de)
WO (1) WO1996010580A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054567A (en) * 1997-04-11 2000-04-25 The United States Of America As Represented By The Department Of Health And Human Services Recombinant proteins of a pakistani strain of hepatitis E and their use in diagnostic methods and vaccines
DE69836485D1 (de) 1997-07-18 2007-01-04 Us Health Hepatitis e-virus aus dem schwein und dessen verwendungen
US6458562B1 (en) 1998-04-09 2002-10-01 The United States Of America As Represented By The Secretary Of Health And Human Services Recombinant proteins of a Pakistani strain of hepatitis E and their use in diagnostic methods and vaccines
AU4451601A (en) * 2000-02-07 2001-08-14 All India Institute Of Medical Sciences Genetically engineered clone of hepatitis e virus (hev) genome which is infectious, its production and uses
CN1345775A (zh) * 2000-09-30 2002-04-24 养生堂有限公司 用于预防、诊断及治疗戊型肝炎病毒的多肽,及它们作为诊断试剂和疫苗
KR100491995B1 (ko) * 2001-06-25 2005-05-30 가부시끼가이샤 도시바 일본인으로부터의 이-형 간염 바이러스로부터 유래하는폴리누클레오티드 프로브 및 프라이머, 이들을 갖는 칩,이들을 갖는 키트, 및 이들에 의한 이-형 간염 바이러스를검출하는 방법
CN100446813C (zh) * 2005-06-24 2008-12-31 东南大学 甲型肝炎-戊型肝炎联合疫苗及其制备方法
CN112225783B (zh) * 2020-09-16 2021-08-31 东莞市朋志生物科技有限公司 Hcv重组抗原及其突变体
CN114957411B (zh) * 2022-05-25 2023-08-18 徐州医科大学 一种正戊型肝病毒属基因c1型病毒orf2重组蛋白及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08504096A (ja) * 1992-09-18 1996-05-07 アメリカ合衆国 Ｅ型肝炎パキスタン株の組換えタンパク質ならびに診断法およびワクチンにおけるそれらの利用
WO1995017501A1 (en) * 1993-12-22 1995-06-29 Abbott Laboratories Monoclonal antibodies against hev orf-2 and methods for using same

Also Published As

Publication number Publication date
JPH11500001A (ja) 1999-01-06
NO326399B1 (no) 2008-11-24
CN1148450C (zh) 2004-05-05
EP0784631A1 (de) 1997-07-23
KR970706300A (ko) 1997-11-03
NZ295056A (en) 1999-06-29
AU712901B2 (en) 1999-11-18
KR100359526B1 (ko) 2003-02-25
AU3830995A (en) 1996-04-26
CN1168698A (zh) 1997-12-24
EP0784631B1 (de) 2011-08-03
JP3889808B2 (ja) 2007-03-07
WO1996010580A2 (en) 1996-04-11
NO971529L (no) 1997-05-26
WO1996010580A3 (en) 1996-05-23
NO971529D0 (no) 1997-04-03

Similar Documents

Publication Publication Date Title
WO1994006913A3 (en) Recombinant proteins of a pakistani strain of hepatitis e and their use in diagnostic methods and vaccines
Purcell The hepatitis C virus: overview
Lagging et al. Immune responses to plasmid DNA encoding the hepatitis C virus core protein
AU738585B2 (en) Synthesis and purification of hepatitis C virus-like particles
DE69132332D1 (en) Hepatitis c-virus-epitope
DK0610250T4 (da) Vaccine med porcint reproduktivt respiratorisk syndrom (PRRS) og diagnose heraf
EP0835315A4 (de) Impstoff gegen den für die atemwegs- und reproduktionserkrankungen beim schwein verantwortlichen virus
WO1993014208A3 (en) Hepatitis e virus vaccine and method
RU96119986A (ru) Вакцина для предохранения свиньи от респираторных или репродуктивных заболеваний, содержащая парагриппозные вирусы
NO20003526D0 (no) Proteiner kodet av polynukleinsyrer fra svinereproduktive- og respiratoriske syndromvirus (PRRSV)
ATE402715T1 (de) Hcv-impfstoff zusammensetzungen
DE69534617D1 (en) Hepatitis b-impfstoff
ATE267256T1 (de) Hepatis e-virus antigene und dessen verwendungen
KR970706300A (ko) E형 간염 파키스탄형 균주의 재조합 단백질 및 이를 이용한 진단방법과 백신(recombinant proteins of a pakistani strain of hepatitis e and their use in diagnostic methods and vaccines)
RU98118186A (ru) Вакцина против репродуктивного и респираторного синдрома у свиней
Fournillier et al. Expression of noncovalent hepatitis C virus envelope E1-E2 complexes is not required for the induction of antibodies with neutralizing properties following DNA immunization
WO2002057314A3 (en) Prevention and treatment of hcv infection employing antibodies directed against conformational epitopes
JPH09500784A (ja) 非ａ、非ｂ型肝炎の診断及び検出に有効である直鎖及び分枝鎖ペプチド
NZ309172A (en) Neutralizing conformational epitopes of chicken anemia virus
MY116208A (en) Improved hcv diagnostic agents
CA2286399A1 (en) Recombinant proteins of a pakistani strain of hepatitis e and their use in diagnostic methods and vaccines
Balayan et al. Serological survey on hepatitis E virus infection in an endemic area: diagnosis potential of enzyme immunoassay for detection of IgG antibody
Chauhan et al. Role of long-persisting human hepatitis E virus antibodies in protection
WO2002089733A3 (en) Recombinant orf2 proteins of the swine hepatitis e virus and their use as a vaccine and as a diagnostic reagent for medical and veterinary applications
Inchauspe Protection and defence mechanisms in HCV infection

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties